Published in Complement on January 01, 1986
C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med (1993) 1.45
Role of innate host defenses in susceptibility to early-onset neonatal sepsis. Clin Perinatol (2010) 1.39
Proteolytic inactivation of plasma C1- inhibitor in sepsis. J Clin Invest (1989) 1.22
Pathophysiology and treatment of septic shock in neonates. Clin Perinatol (2010) 1.17
Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin Exp Immunol (1993) 1.15
In vivo effects of monoclonal antibodies that functionally inhibit complement regulatory proteins in rats. J Exp Med (1994) 1.06
Disruption of the C5a receptor gene increases resistance to acute Gram-negative bacteremia and endotoxic shock: opposing roles of C3a and C5a. Mol Immunol (2007) 1.01
C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression. J Virol (2006) 0.96
Activation of the complement system in baboons challenged with live Escherichia coli: correlation with mortality and evidence for a biphasic activation pattern. Infect Immun (1993) 0.92
Modulation of leukocyte recruitment and IL-8 expression by the membrane attack complex of complement (C5b-9) in a rabbit model of antigen-induced arthritis. Inflammation (2002) 0.88
Bacterial chaperone protein, Skp, induces leukocyte chemotaxis via C5a receptor. Am J Pathol (2004) 0.83
Biological properties of human C5a: selected in vitro and in vivo studies. Clin Exp Immunol (1988) 0.80
C5a receptor deficiency alters energy utilization and fat storage. PLoS One (2013) 0.80
Relative contribution of contact and complement activation to inflammatory reactions in arthritic joints. Ann Rheum Dis (1992) 0.77
Complement activation is involved in biological responses to leukocyte adsorptive apheresis. Dig Dis Sci (2006) 0.77
A model for the interplay of inflammatory mediators in sepsis--a study in 48 patients. Intensive Care Med (1990) 0.75
Effect of programmed endoscopic follow-up examinations on the rebleeding rate of gastric or duodenal peptic ulcers treated by injection therapy: a prospective, randomized controlled trial. Endoscopy (1998) 1.83
Stimulation of DNA synthesis in mouse lymphoid cells by polyanions in vitro. I. Target cells and possible mode of action. Eur J Immunol (1973) 1.80
Significance of phospholipase A for prostaglandin formation. Ann N Y Acad Sci (1971) 1.59
[Pantoprazole-induced hepatitis]. Dtsch Med Wochenschr (2003) 1.51
Performance of various mathematical methods for computer-aided processing of radioimmunoassay results. Clin Chim Acta (1978) 1.40
Alternative pathway for the activation of complement in human serum. Formation and composition of the complex with cobra venom factor that cleaves the third component of complement. Hoppe Seylers Z Physiol Chem (1974) 1.29
Stimulation of B-cells by dextran sulphate in vitro. Immunology (1973) 1.23
Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis. Gut (1997) 1.23
Treatment of human complement components C4 and C3 with amines or chaotropic ions. Evidence of a functional and structural change that provides uncleaved C4 and C3 with properties of their soluble activated froms, C4b and C3b. Scand J Immunol (1981) 1.22
A new function of the activated third component of complement: binding to C5, an essential step for C5 activation. Immunology (1978) 1.20
Complement activation by the properdin system: formation of a stoichiometric. C3 cleaving complex of properdin factor B with C36. Immunochemistry (1977) 1.19
Formation and composition of the C3 activating enzyme complex of the properdin system. Sequential assembly of its components on solid-phase trypsin-agarose. Z Immunitatsforsch Exp Klin Immunol (1975) 1.14
Prostaglandin release from and formation in perfused frog intestine. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol (1968) 1.13
Stimulation of DNA synthesis in mouse lymphoid cells by polyanions in vitro. II. Relationship between adjuvant activity and stimulation of DNA synthesis by polyanions. Eur J Immunol (1973) 1.12
Diagnosis of porphyrias by ion-pair high-performance liquid chromatography. J Chromatogr (1980) 1.12
Contraction of the guinea-pig ileum induced by anaphylatoxin independent of histamine release. Int Arch Allergy Appl Immunol (1970) 1.10
Purification and partial amino acid sequence of classical anaphylatoxin from pig serum: identification with Des-Arg-C5a. Hoppe Seylers Z Physiol Chem (1980) 1.09
Effects of local anaesthetics on prostaglandin biosynthesis in vitro. Biochim Biophys Acta (1974) 1.09
Actions of anaphylatoxin on circulation and respiration of the guinea pig. Int Arch Allergy Appl Immunol (1967) 1.06
Biological activities of C5a and C5adesArg from hog serum. Int Arch Allergy Appl Immunol (1980) 1.05
Activation, activities and pharmacologically active products of complement. Pharmacol Rev (1974) 1.05
Induction of platelet aggregation by the complement-derived peptides C3a and C5a. Naunyn Schmiedebergs Arch Pharmacol (1976) 1.04
Purification and some properties of factor D of the human properdin system. Z Immunitatsforsch Immunobiol (1976) 1.04
Purification and some properties of a heat labile serum factor (UP); identity with glycine-rich beta-glycoprotein and properdin factor B. Hoppe Seylers Z Physiol Chem (1973) 1.03
Role of phospholipase A2 in prostaglandin formation. Adv Prostaglandin Thromboxane Res (1978) 1.02
[Formation by phospholipase A of SRS-C in perfused guinea pig lung. Identification with prostaglandin]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol (1969) 0.99
Purification of a human serum protein ("factor E") which enhances cobra venom factor-induced indirect lysis. Identification with the fifth component of complement. Z Immunitatsforsch Exp Klin Immunol (1976) 0.96
Prostaglandin: liberation from and formation in perfused frog intestine. Naunyn Schmiedebergs Arch Pharmakol (1970) 0.96
Functional identity of anaphylatoxin preparations obtained from different sources and by different activation procedures. 1. Pharmacological experiments. Eur J Pharmacol (1970) 0.95
Preparation and some properties of anaphylatoxin from hog serum. Biochem Pharmacol (1968) 0.95
Mixed lymphocyte culture stimulatory and responding capacity of lymphocytes from patients with lymphoproliferative diseases. Clin Exp Immunol (1975) 0.94
The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass. J Thorac Cardiovasc Surg (1991) 0.94
Aggregation of leukocytes induced by the complement-derived peptides C3a and C5a and by three synthetic formyl-methionyl peptides. Int Arch Allergy Appl Immunol (1980) 0.93
Effect of L-asparaginase and hydrocortisone on human lymphocyte transformation and production of a mononuclear leucocyte chemotactic factor in vitro. Immunology (1974) 0.93
Multiple effects of a diamidine (propamidine) on complement activation. Immunology (1979) 0.91
Formation of anaphylatoxin in rat plasma, a specific enzymic process. Biochem Pharmacol (1966) 0.91
Incompatibility between C3b and B of guinea-pig and man and its influence on the titration of the alternative pathway factors D and B in these two species. Immunology (1976) 0.91
Comparison of Naja n. naja and Naja h. haje cobra-venom factors: correlation between binding affinity for the fifth component of complement and mediation of its cleavage. Immunobiology (1980) 0.91
Interference of propamidine with binding of the fifth component of complement to surface-fixed C3b, and with C5 activation. Immunology (1979) 0.90
Loss and recovery of sensitivity of guinea-pig isolated ileum to the spasmogenic action of the complement peptide C5adesArg. Br J Pharmacol (1985) 0.89
Mechanisms of complement activation by crystalline cholesterol. Mol Immunol (1985) 0.88
Effects of the cleavage peptides, C3q and C3ai, from the third component of hog complement on leukocyte accumulation and vascular permeability in vivo. Naunyn Schmiedebergs Arch Pharmacol (1978) 0.88
[Is the hyperostotic spondylosis deformans a diabetic osteopathy?]. Fortschr Geb Rontgenstr Nuklearmed (1969) 0.88
Effect of hog anaphylatoxin (C 5a) on vascular permeability and leukocyte emigration in vivo. Naunyn Schmiedebergs Arch Pharmacol (1976) 0.87
The anaphylatoxin-forming system. Ergeb Physiol (1967) 0.87
Improved separation and detection of free porphyrins by high-performance liquid chromatography. J Chromatogr (1984) 0.87
Synergism between phospholipase A and various peptides and SH-reagents in causing haemolysis. Naunyn Schmiedebergs Arch Pharmakol (1970) 0.87
Group experiments on the radioimmunological insulin determination. Horm Metab Res (1974) 0.86
Interleukins and their antagonists but not TNF and its receptors are released in post-ERP pancreatitis. Eur J Gastroenterol Hepatol (1998) 0.84
Release of glutamate and of free fatty acids in vasogenic brain edema. J Neurosurg (1989) 0.84
[Separation of an anaphylatoxin-forming principle from other venom components in cobra venom]. Experientia (1964) 0.84
Complement activation in human lymph: modulation by the contact activation system and by leukocytes. Int Arch Allergy Appl Immunol (1986) 0.83
Formation of anaphylatoxin in human serum. Experientia (1969) 0.83
[Histamine-independent effects of anaphylatoxin on smooth muscle of isolated organs]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol (1969) 0.83
Role of the N-terminal regions of hog C3a, C5a and C5a-desArg in their biological activities. Mol Immunol (1986) 0.82
[Effect of anaphylatoxin (AT) upon capillary permeability in guinea pig skin]. Naunyn Schmiedebergs Arch Pharmakol (1970) 0.82
Histamine release, formation of prostaglandin-like activity (SRS-C) and mast cell degranulation by the direct lytic factor (DLF) and phospholipase A of cobra venom. Naunyn Schmiedebergs Arch Pharmacol (1975) 0.82
Pharmacological characterization of the slow component of deactivation of guinea-pig isolated ileum to the spasmogenic action of C5adesArg. Br J Pharmacol (1985) 0.82
Captopril in children with dilated cardiomyopathy: acute and long-term effects in a prospective study of hemodynamic and hormonal effects. Pediatr Cardiol (1990) 0.82
[Relation between lymphocytes and kidney tubule epithelium in the human kidney]. Klin Wochenschr (1970) 0.82
Creatine kinase determination: a European evaluation of the creatine kinase determination in serum, plasma and whole blood with the Reflotron system. Eur J Clin Chem Clin Biochem (1991) 0.82
Activation of lymphocyte subpopulations in patients with chronic lymphocytic leukemia. Z Immunitatsforsch Immunobiol (1978) 0.81
Function of the activated fourth component of complement (C4b) in activation of C2. FEBS Lett (1982) 0.81
[Prostaglandine in a darmstoff preparation from frog intestine]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol (1965) 0.81
Purification and some properties of a kininogenase from human plasma activated by surface contact. Hoppe Seylers Z Physiol Chem (1972) 0.80
Quantification of vanadium in serum by electrothermal atomic absorption spectrometry. Clin Chem (1996) 0.80
Role of histamine in the spasmogenic effect of the complement peptides C3a and C5a-desArg (classical anaphylatoxin). Agents Actions (1982) 0.80
Stimulation of B cells by poly A: poly U and poly I: poly C in vitro. Immunology (1974) 0.80
Xenotransplantation of parathyroids in rats using barium-alginate and polyacrylic acid multilayer microcapsules. Exp Toxicol Pathol (2001) 0.80
[Phenprocoumon-induced liver failure]. Dtsch Med Wochenschr (2003) 0.80
Binding of phospholipase A to the cirect lytic factor revealed by the interaction of Ca 2+ with the haemolytic effect. Biochim Biophys Acta (1971) 0.80
Effect of media composition on long-term in vitro stability of barium alginate and polyacrylic acid multilayer microcapsules. Biomaterials (2000) 0.80
Amino-acid sequence and disulfide linkages of the anaphylatoxin, des-Arg omega-C5a, from porcine serum. Hoppe Seylers Z Physiol Chem (1984) 0.79
Effects of hydrocortisone treatment and whole body irradiation on mouse lymphocyte stimulation in vitro. Immunology (1973) 0.79
[Serum kininogenases and their activation]. Hoppe Seylers Z Physiol Chem (1968) 0.79
Incompatibility between complement components C3 and C5 of guinea-pig and man, an indication of their interaction in C5 activation by classical and alternative C5 convertases. Scand J Immunol (1979) 0.79
Activation of the classical complement pathway by a polysaccharide from sugar cane. Immunopharmacology (1982) 0.79
Activation of the complement system. Agents Actions (1983) 0.79
Lymphocyte transformation and production of a human mononuclear leucocyte chemotactic factor in patients with Hodgkin's disease. Clin Exp Immunol (1974) 0.79
Mode-locked laser diode with an ultrafast integrated uni-traveling carrier saturable absorber. Opt Lett (2005) 0.79
Binding characteristics of the complement peptides C3a and C5a-desArg to cellulose nitrate filters in Boyden chambers. Agents Actions Suppl (1983) 0.79
Fast deactivation of guinea-pig isolated ileum to C5adesArg: a possible cyclic AMP-dependent mechanism. Br J Pharmacol (1985) 0.78
Significance of direct and indirect kinin formation by plasmin in human plasma. Biochem Pharmacol (1971) 0.78
Indomethacin treatment of acute experimental pancreatitis in the rat. Scand J Gastroenterol (1978) 0.78
Chemotactic effects of the complement-derived peptides C3a, C3ai and C5a (classical anaphylatoxin) on rabbit and guinea-pig polymorphonuclear leukocytes. Naunyn Schmiedebergs Arch Pharmacol (1978) 0.78
Discrepant results for cardiac troponin T and troponin I in chronic myopathy, depending on instrument and assay generation. Clin Chem (1996) 0.78
Potentiation of haemolysis by the combined action of phospholipase A and a basic peptide containing S-S-bonds (viscotoxin B). Experientia (1971) 0.78
The use of cluster analysis in clinical chemical diagnosis of liver diseases. J Clin Chem Clin Biochem (1990) 0.77
[Pharmacokinetics of 9 -fluorhydrocortisone]. Arzneimittelforschung (1971) 0.77
Chain structure of cobra venom factor from Naja naja and Naja haje venom. Scand J Immunol (1982) 0.77
Direct haemolytic activity of phospholipase A. Biochim Biophys Acta (1972) 0.77
[Cardiac effects of antikaliuretic diuretics-clinical and biochemical investigation (author's transl)]. Klin Wochenschr (1977) 0.77
Factors in cobra venoms affecting the complement system. Toxicon (1982) 0.77
Effect of different penicillin derivatives on complement components in human serum. Int Arch Allergy Appl Immunol (1984) 0.77
Immunization against cobra venom. Experientia (1971) 0.76
[Spontaneous formation of prostaglandin in the isolated frog intestine]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol (1968) 0.76
Formation of mixed aggregates of human polymorphonuclear leukocytes and platelets by C5a-desArg. Complement Inflamm (1991) 0.76
Effect of different sulfonamides on the human serum complement system. Int Arch Allergy Appl Immunol (1985) 0.76
Multicentre evaluation of an immunological rapid test for the detection of troponin T in whole blood samples. Eur J Clin Chem Clin Biochem (1996) 0.76